TAŞ TORUN, Y. Et Al. 2022. Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial. APPLIED NEUROPSYCHOLOGY-CHILD , vol.11, no.4 , 567-578.

TAŞ TORUN, Y., Isik Taner, Y., GÜNEY, E., & İŞERİ, E., (2022). Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial. APPLIED NEUROPSYCHOLOGY-CHILD , vol.11, no.4, 567-578.

TAŞ TORUN, YASEMİN Et Al. "Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial," APPLIED NEUROPSYCHOLOGY-CHILD , vol.11, no.4, 567-578, 2022

TAŞ TORUN, YASEMİN T. Et Al. "Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial." APPLIED NEUROPSYCHOLOGY-CHILD , vol.11, no.4, pp.567-578, 2022

TAŞ TORUN, Y. Et Al. (2022) . "Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial." APPLIED NEUROPSYCHOLOGY-CHILD , vol.11, no.4, pp.567-578.

@article{article, author={YASEMİN TAŞ TORUN Et Al. }, title={Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial}, journal={APPLIED NEUROPSYCHOLOGY-CHILD}, year=2022, pages={567-578} }